- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03832114
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 Glomerulopathy
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- Novartis Investigative Site
-
Paris, France, 75015
- Novartis Investigative Site
-
-
-
-
-
Essen, Germany, 45147
- Novartis Investigative Site
-
-
-
-
BG
-
Ranica, BG, Italy, 24020
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28041
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
-
-
-
-
London, United Kingdom, W12 0NN
- Novartis Investigative Site
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Novartis Investigative Site
-
-
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for Cohort A and B:
- Written informed consent must be obtained before any assessment is performed
- Male and female patients between the ages of 18 to 65 (inclusive) at screening
- C3G patients wit proteinuria
- Able to communicate well with the investigator, to understand and comply with the requirements of the study
- At screening and baseline visits, patients must weigh at least 35 kg
- Supine vital signs should be within the following ranges :
oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm
.
Inclusion Criteria for Cohort A:
- Estimated GFR (using the CKD-EPI formula) or measured GFR ≥30 mL/min per 1.73 m2 for patients on a maximum recommended or maximum tolerated dose of an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
- UPCR ≥ 100 mg/mmol (equivalent to ≥ 1 g/24h total urinary protein excretion)
- Prior to entry, all patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB for at least 30 days.
Inclusion Criteria for Cohort B:
- No histological/laboratory/clinical signs of allorejection
- If applicable, induction treatment after allotransplantation needs to be completed >30 days before inclusion.
- Transplantation of a kidney allograft >90 days before inclusion
- Patients need to be on a stable dose of immunosuppressive regimen prior to inclusion. Any approved treatments are allowed for this purpose.
Exclusion Criteria for Cohort A and B:
- Use of other investigational drugs at the time of enrollment, or within 5 half-lives of randomization, or within 30 days, whichever is longer; or longer if required by local regulations
- A history of clinically significant ECG abnormalities,
- Known family history or known presence of long QT syndrome or Torsades de Pointes
- Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- Women of child bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug.
- History of immunodeficiency diseases, or a positive HIV test result.
- Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).
- Patients who cannot receive vaccinations against N. meningitidis, S. pneumoniae, or H. influenzae
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A - no kidney transplant
C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
|
Increasing doses of LNP023 up to 200 mg.
|
Experimental: Cohort B - kidney transplant
C3G patients who have received a kidney transplant and have C3G recurrence.
|
Increasing doses of LNP023 up to 200 mg.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)
Time Frame: Week 12
|
Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection
|
Week 12
|
Cohort B: Change From Baseline in C3 Deposit
Time Frame: Week 12
|
Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy)
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR)
Time Frame: Week 12: Day 84
|
Ratio to baseline UPCR derived from 24 hour urine collection
|
Week 12: Day 84
|
Change From Baseline in Urine Protein (UP) Excretion
Time Frame: Week 12: Day 84
|
Ratio to baseline UP excretion derived from 24 hour urine collection
|
Week 12: Day 84
|
Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion
Time Frame: Week 12: Day 84
|
Ratio to baseline UACR excretion derived from 24 hour urine collection
|
Week 12: Day 84
|
Change From Baseline Change in Urinary Albumin (UA) Excretion
Time Frame: Week 12: Day 84
|
Ratio to baseline UA excretion derived from 24 hour urine collection
|
Week 12: Day 84
|
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time Frame: Day 84
|
Effect of LNP023 on estimated glomerular filtration rate (eGFR)
|
Day 84
|
Change From Baseline in Serum Creatinine
Time Frame: Week 12: Day 84
|
The effect of LNP023 on renal function - serum creatinine
|
Week 12: Day 84
|
Change From Baseline in Creatinine Clearance
Time Frame: Week 12: Day 84
|
The effect of LNP023 on renal function - creatinine clearance
|
Week 12: Day 84
|
Number of Patients With Hematuria
Time Frame: Week 12: Day 84
|
The effect of LNP023 on renal function - hematuria
|
Week 12: Day 84
|
Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void
Time Frame: Week 9: Day 64
|
Ratio to baseline of UPCR reduction derived from total cumulative urinary excretion first morning void
|
Week 9: Day 64
|
Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void
Time Frame: Week 9: Day 64
|
UACR reduction derived from total cumulative urinary excretion first morning void
|
Week 9: Day 64
|
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC)
Time Frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
The area under the plasma concentration-time curve calculated from time zero to the last quantifiable concentration point (hr*ng/mL)
|
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC)
Time Frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
The area under the plasma concentration-time curve calculated to the end of the dosing interval (hr*ng/mL)
|
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
Observed Maximum Concentration After Drug Administration (Cmax)
Time Frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
The observed maximum plasma concentration (ng/mL)
|
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
Observed Minimum Concentration After Drug Administration (Ctrough)
Time Frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
The concentration that is just prior to the beginning of, or at the end, of a dosing interval (ng/mL)
|
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
Time to Reach the Maximum Plasma Concentration (Tmax)
Time Frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
The time to reach peak or maximum concentration (hr)
|
Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
|
Summary of Change From Baseline Complement C3 Biomarker in Serum
Time Frame: Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
|
To assess the effect of LNP023 on alternative complement pathway hyperactivity.
|
Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
|
Ratio to Baseline Summary of Plasma Bb
Time Frame: Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
|
To assess the relationship between LNP023 dose and pharmacodynamic biomarker levels of blood Bb
|
Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLNP023X2202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glomerulonephritis
-
Celldex TherapeuticsTerminatedC3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type IIUnited States
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedC3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and IIINetherlands, Australia, Belgium
-
Mario Negri Institute for Pharmacological ResearchAlexion PharmaceuticalsCompletedIC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative GlomerulonephritisItaly
-
University Magna GraeciaCompletedIGA GlomerulonephritisItaly
-
Apellis Pharmaceuticals, Inc.Active, not recruitingC3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...United States, Spain, France, Germany, United Kingdom, Netherlands, Brazil, Israel, Japan, Australia, Austria, Italy, Switzerland, Korea, Republic of, Czechia, Belgium, Argentina, Canada, Poland
-
Apellis Pharmaceuticals, Inc.Active, not recruitingC3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...United States, Australia, Brazil, Czechia, France, Italy, Korea, Republic of, Netherlands, Spain, Switzerland, United Kingdom
-
Apellis Pharmaceuticals, Inc.AvailableC3G | IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Complement 3 Glomerulopathy | Complement 3 Glomerulopathy (C3G) | Complement 3 Glomerulonephritis | Dense Deposit Disease | DDD | Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis (MPGN) | Immune Complex Membranoproliferative...United States
-
Assiut UniversityUnknownMembranoproliferative Glomerulonephritis
-
Mayo ClinicCompletedGlomerulonephritis, MembranoproliferativeUnited States
-
Nagoya UniversityRohto Pharmaceutical Co., Ltd.Completed
Clinical Trials on LNP023
-
Novartis PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria PNHLithuania, Japan, Czechia
-
Novartis PharmaceuticalsRecruitingC3 GlomerulopathySpain, France, Germany, Switzerland, United States, Japan, Turkey, China, United Kingdom, Italy, Argentina, Brazil, Greece, Israel, Netherlands
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsRecruitingAge-Related Macular DegenerationChina, United States, Puerto Rico, United Kingdom
-
Novartis PharmaceuticalsRecruitingAtypical Hemolytic Uremic SyndromeJapan, Turkey
-
Novartis PharmaceuticalsRecruitingLupus NephritisFrance, Spain, Israel, Turkey, United States, Germany, India, Hungary, Malaysia, Portugal, Brazil, China, Puerto Rico, Hong Kong, Mexico, Singapore
-
Novartis PharmaceuticalsRecruitingC3GSpain, France, Switzerland, Germany, Greece, Turkey, Canada, India, United States, Czechia, Japan, Argentina, Brazil, Italy, Israel, United Kingdom, China, Belgium, Netherlands
-
Novartis PharmaceuticalsActive, not recruitingIgA NephropathyUnited States, Taiwan, Czechia, Germany, Hungary, India, Turkey, Belgium, Netherlands, Singapore, Australia, Canada, Italy, Korea, Republic of, Spain, Thailand, Denmark, Slovenia, United Kingdom, Argentina, Brazil, Israel, Japan, France, Swed... and more
-
Novartis PharmaceuticalsRecruitingAtypical Hemolytic Uremic SyndromeChina, Korea, Republic of, Austria, Taiwan, Greece, Czechia, United States, Japan, Brazil, United Kingdom, India, Slovakia, Slovenia
-
Novartis PharmaceuticalsCompletedIgA NephropathyColombia, Taiwan, Czechia, India, Turkey, Belgium, Netherlands, Singapore, Australia, Korea, Republic of, Thailand, Argentina, Germany, Israel, Japan, Sweden, United Kingdom, Brazil, China, Hong Kong, Norway, Finland, France, Denmark, M...